Your Article Summary
See Latest ArticlesPrimary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
Chugai Pharmaceutical Co., 07/01/09
Chugai Pharmaceutical Co., Ltd. announced that Phase III study of the recombinant human erythropoietin "Epogin Injection" achieved the primary endpoint by significantly reducing the theoretical transfusion rate in patients with chemotherapy induced anemia.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie
Anti-Cancer Drugs, 12/09/09
Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy
Anti-Cancer Drugs, 12/09/09
Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy
Medicinal Research Reviews, 12/09/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09
Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09